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Summary 
Osteoclasts are involved in the catabolism of the bone matrix and eliminate the 
resulting degradation products through transcytosis, but the molecular mechanism and 
regulation of transcytosis remain poorly understood.  Upon differentiation, osteoclasts 
express vesicular glutamate transporter 1 (VGLUT1) that is essential for vesicular 
storage and subsequent exocytosis of glutamate in neurons.  VGLUT1 is localized in 
transcytotic vesicles and accumulates L-glutamate.  Osteoclasts secrete L-glutamate 
and the bone degradation products upon stimulation with KCl or ATP in a 
Ca2+-dependent manner.  KCl- and ATP-dependent secretion of L-glutamate was 
absent in osteoclasts prepared from VGLUT1-/- knockout mice.  Osteoclasts express 
mGluR8, a class III metabotropic glutamate receptor.  Its stimulation by a specific 
agonist inhibits secretion of L-glutamate and bone degradation products, while its 
suppression by a specific antagonist stimulates bone resorption.  Finally, it was found 
that VGLUT1-/- mice develop osteoporosis.  Thus, in bone-resorbing osteoclasts, 
L-glutamate and bone degradation products are secreted through transcytosis and the 
released L-glutamate is involved in autoregulation of transcytosis.  Glutamate 
signaling may play an important role in the bone homeostasis.   
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Introduction 
Bone resorption is an essential component of bone remodeling during the development, 
growth and turnover of bone.  An imbalance contributes to the pathogenesis as well as 
the etiology of metabolic diseases such as osteoporosis and osteopetrosis (Eriksen, 1986; 
Rodan and Martin, 2000; Boyle et al, 2003).  Osteoclasts are multinuclear cells 
originating from monocyte/macrophage lineage cells and are primarily responsible for 
bone resorption (Baron et al, 1994; Blair, 1998; Väänänen et al, 2000).  During the 
resorption process, osteoclasts are highly polarized, form tightly sealed compartments (i. 
e., resorption lacunae) on the bone surface, and secrete protons, chloride anions and 
proteases through the ruffled border, resulting in the degradation of the bone matrix.  
To transport a large amount of degradation products, osteoclasts develop an inwardly 
polarized membrane traffic called transcytosis: inorganic and organic degradation 
products and cathepsin K are taken up at the ruffled border through endocytosis, 
packaged into transcytotic vesicles, transported along microtubules to the basolateral 
plasma membrane, and then secreted through exocytosis (Nesbitt and Horton, 1997; 
Salo et al, 1997; Mulari et al, 2003).  The overall secretory processes are believed to be 
highly organized and coordinated with other bone functions, although the mechanisms 
and regulation of transcytosis remain poorly understood. 
       L-Glutamate, an excitatory neurotransmitter of the central nervous system, acts 
as an intercellular messenger in peripheral non-neuronal cells, in which L-glutamate is 
stored in secretory vesicles and secreted through regulated exocytosis and, thus, enables 
intercellular chemical transmission in a paracrine- or autocrine manner (Moriyama and 
Yamamoto, 2004).  Although there is evidence for L-glutamate signaling in bone, its 
physiological significance has not been established (Serre et al, 1999; Bhangu et al, 
2001; Hinoi et al, 2001; Skerry and Taylor, 2001; Mason, 2004).  Bone cells express 
the GLAST-type Na+-dependent plasma membrane transporter, which terminates 
L-glutamate signals (Skerry and Taylor, 2001; Mason, 2004).  Bone cells also express 
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various functional glutamate receptors, and their stimulation affect the functions of 
osteoblasts and osteoclasts (Skerry and Taylor, 2001; Mason, 2004).  However, it is 
still unresolved where, when and how L-glutamate appears as an intercellular messenger 
in bone.  Although L-glutamate has been suggested to originate from 
L-glutamate-containing nerve terminals (Serre et al, 1999) or osteoblasts (Bhangu et al, 
2001; Hinoi et al, 2002), secretion of L-glutamate from nerve terminals has not been 
detected.  Furthermore, the mode of secretion of L-glutamate from osteoblasts differs 
from that of the exocytosis of L-glutamate in CNS or endocrine cells. 
       Vesicular glutamate transporter (VGLUT) plays an essential role in 
L-glutamate signaling through vesicular storage of L-glutamate (Fremeau et al, 2004a; 
Moriyama and Yamamoto, 2004).  There are three isoforms of VGLUT: VGLUT1, 
VGLUT2 and VGLUT3.  VGLUT is a potential marker for the sites of L-glutamate 
signaling and can help reveal details of the mode of glutamate signaling in the body 
(Moriyama and Yamamoto, 2004). 
       In the present study, we examined the expression and localization of VGLUT in 
bone tissue to determine how L-glutamate becomes an intercellular messenger.  We 
found an unexpected link between L-glutamate signaling and bone resorption.  We 
show that [I] mature osteoclasts possess VGLUT1-containing transcytotic vesicles and 
thus secrete L-glutamate and bone degradation products through transcytosis.  [II] This 
glutamate signaling is involved in autoregulation of transcytosis.  [III] Impairment of 
the glutamate signaling stimulates bone resorption and may contribute to the 
development of osteoporosis.   
 
 
Results 
VGLUT1 was expressed in osteoclasts 
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RT-PCR analysis demonstrated that osteoclasts derived from bone marrow cells 
contained mRNA encoding VGLUT1 and that other types of bone cells including 
primary osteoblasts, stroma cells and clonal bone cells did not express this mRNA 
(Figure 1A).  Neither VGLUT2 nor VGLUT3 was expressed in any of the bone cells 
analyzed (Figure 1B).  Northern blot analysis revealed mRNA of VGLUT1 in mature 
osteoclasts but not in undifferentiated cells (Figure 1C).  Upon stimulation with 
RANKL, a receptor activator of the nuclear factor κB ligand, murine macrophage RAW 
264.7 cells can differentiate into osteoclasts (Toyomura et al, 2003) that then express the 
VGLUT1 gene (Figure 1A, C).  These results indicate that the VGLUT1 gene was 
specifically expressed in osteoclasts during differentiation and that expression of the 
VGLUT2 and VGLUT3 genes in bone cells was negligible or below the detection limit 
of our assay. 
Immunoblotting with VGLUT1 antibodies revealed that an immunoreactive 
polypeptide with an apparent molecular mass similar to that of VGLUT1 (~62 kDa) 
appeared in RAW264.7 cells upon treatment of RANKL, while expression of the 
housekeeping vacuolar H+-ATPase (V-ATPase) subunit was the same before and after 
differentiation (Figure 1D). 
Inducible expression of VGLUT1 immunoreactivity in RAW264.7 cells treated 
with RANKL was confirmed by immunohistochemistry: VGLUT1 immunoreactivity 
appeared three days after induction and reached a steady state level after seven days 
(Figure 1E).  The presence of VGLUT1 immunoreactivity in tartrate-resistant acid 
phosphatase (TRAP)-positive osteoclasts was confirmed in the femurs of VGLUT1+/+ 
(wild type) mice but not in those of VGLUT1-/- mice (Figure 1F).  Essentially the same 
results were obtained in osteoclasts prepared from VGLUT1+/+ (wild type) mice but not 
in those of VGLUT1-/- mice (supplementary information, Figure S1).  Overall, these 
results demonstrate that VGLUT1 appeared in osteoclasts during osteoclastogenesis. 
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VGLUT1 was associated with transcytotic vesicles 
To identify VGLUT1-containing organelles, we performed immunohistochemical analyses.  
After culturing on bone, an actin ring was observed, indicating the site of bone digestion 
(Figure 2A).  The VGLUT1 immunoreactivity exhibited a punctated distribution throughout 
the cells and was especially abundant in the basolateral region, but less in the ruffled border 
region (Figure 2A, B).  VGLUT1 was roughly co-localized with microtubules but not with 
actin (Figure 2A, B).  VGLUT1 did not seem to be co-localized with Lamp2, TGN38, 
GM130 or transferrin receptor (TfR), which are markers for lysosomes, the Golgi apparatus, 
endosomes and recycling vesicles, respectively (supplementary information, Figure S2), but 
rather was partially co-localized with lysobisphosphatidic acid, a phospholipid abundant in 
late endosomes (Figure 2C) and cathepsin K (Figure 2D), both of which are associated with 
the transcytotic pathway after endocytosis (Vääräniemi et al, 2004).  Furthermore, VGLUT1 
immunoreactivity was, in part, co-localized with the internalized fluorescent bone 
degradation products (Figure 2E).  These results suggest that VGLUT1 was associated with 
the vesicles involved in the transcytotic pathway, such as transcytotic vesicles.   
       VGLUT1-containing vesicles were identified through double immunoelectron 
microscopy.  Consistent with the immunohistochemical observations made above, there 
were at least three types of vesicles associated with immunogold particles specific for 
VGLUT1 and bone degradation products: many clear vesicles with an average diameter of 
~300 nm in which VGLUT1 was present but in which immunoreactivity for bone degradation 
products was not detected (Figure 3A), larger vesicles located near basolateral regions that 
contained many VGLUT1 immunogold particles and some particles for bone degradation 
products (Figure 3B), and larger vesicles located near the ruffled border membrane that 
contained many immunogold particles for bone degradation products and a few immunogold 
particles for VGLUT1 (Figure 3C).  We concluded that a population of VGLUT1 was 
associated with the transcytotic vesicles that contain bone degradation products.  The 
dynamics of these vesicles during transcytosis is discussed later. 
 7 
 
VGLUT1 in osteoclasts was functional 
We then determined whether VGLUT1-containing vesicles accumulate L-glutamate.  
Generally, V-ATPase supplies the driving force for the vesicular storage of L-glutamate 
(Maycox et al, 1990; Moriyama and Yamamoto, 2004).  We prepared membrane vesicles 
from RAW264.7 cells treated with or without RANKL.  Upon the addition of ATP, a 
substantial amount of L-glutamate was taken up by vesicles isolated from RAW264.7 cells 
treated with RANKL and much less was taken up by those isolated from undifferentiated 
control RAW264.7 cells (Figure 4A).  The ATP-dependent L-glutamate uptake was blocked 
by carbonyl cyanide-m-chlorophenylhydrazone (CCCP, a proton conductor), bafilomycin A1 
(V-ATPase inhibitor, Bowman et al, 1988), and Evans blue (an inhibitor of VGLUT, Roseth 
et al, 1998), but not affected by 10 mM D, L-aspartate (Figure 4B).  A low concentration of 
Cl- (4 mM) was required for L-glutamate uptake; in the absence of Cl-, the uptake decreased 
to background level (Figure 4B).  All results were fully consistent with the properties of 
VGLUT-mediated L-glutamate transport (Moriyama and Yamamoto, 2004), and 
demonstrated VGLUT1-dependent vesicular storage of L-glutamate in bone-resorbing 
RAW264.7 cells treated with RANKL.  
 
Osteoclasts secreted L-glutamate through transcytosis 
Do osteoclasts secrete L-glutamate?  Since the exocytosis of L-glutamate is usually driven 
by membrane depolarization, we measured the L-glutamate present in the medium after 
depolarization of osteoclasts with KCl.  KCl at 50 mM depolarizes bone-resorbing 
osteoclasts through a voltage-gated K+ channel (Kajiya et al, 2003).  We found that KCl 
stimulated the secretion of L-glutamate from RAW264.7 cells treated with RANKL and to 
a lesser extent from undifferentiated control cells (Figure 5A).  The KCl-evoked 
L-glutamate secretion was dependent on extracellular Ca2+ and temperature: depletion of 
Ca2+ by treatment with EGTA-AM inhibited the secretion by 80% and low temperature 
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(24 °C) abolished the secretion (Figure 5B).  Consistent with its effect on the vesicular 
storage of L-glutamate (Figure 4), bafilomycin A1 decreased L-glutamate secretion (Figure 
5B).  These properties are similar to those reported for the regulated exocytosis of 
L-glutamate by neurons and endocrine cells (Moriyama and Yamamoto, 2004). 
       Since a population of VGLUT1 is associated with transcytotic vesicles, secretion 
of L-glutamate may accompany, at least in part, the secretion of bone degradation products.  
As expected, KCl stimulated secretion of fluorescent bone degradation products (Figure 
5C).  The secretion also required extracellular Ca2+ and was sensitive to temperature and 
bafilomycin A1 (Figure 5C).  Bafilomycin A1 is also known to inhibit transcytosis 
(Palokangas et al, 1997; Stenbeck and Horton, 2004).  Furthermore, nocodazole, a reagent 
that dissociates microtubules and, through this, inhibits transcytosis (Stenbeck and Horton, 
2004), inhibited the secretion of both L-glutamate and bone degradation products to a 
similar extent (Figure 5B, C).  These results support the idea that L-glutamate was 
co-secreted with bone degradation products through transcytosis. 
       It is important to ask what kinds of stimuli trigger transcytosis under physiological 
conditions.  We found that ATP at 1 mM stimulated the secretion of both L-glutamate 
(Figure 5D) and bone degradation products (Figure 5E), and was blocked by 
pyridoxalphosphate-6-azophenyl-2’-4’-disulfonic acid (PPADS), a selective antagonist of 
ionotropic purinergic receptors (Ralevic and Burnstock, 1998).  Since ATP is secreted from 
osteoblasts upon mechanical stimulation and depolarizes osteoclasts so as to increase the 
cytosolic concentration of Ca2+ via ionotropic purinergic receptors (Naemsch et al, 2001; 
Romanello et al, 2001), the results suggest that ATP was one of the physiological stimuli for 
secretion of L-glutamate and bone degradation products.   
 
L-Glutamate secretion from osteoclasts from VGLUT1 -/- mice 
We then assessed L-glutamate secretion from osteoclasts prepared from VGLUT1 -/- mice.  
The number and morphology of osteoclasts from VGLUT1 +/- heterozygotes and VGLUT1 -/- 
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homozygotes were apparently comparable to those of wild type osteoclasts.  As shown in 
Figure 6 A and B, KCl stimulated the secretion of L-glutamate in osteoclasts from wild type 
and heterozygotic mice by a factor of ~2.  The KCl-evoked secretion of L-glutamate was not 
observed in the case of osteoclasts from VGLUT1 -/- homozygotes (Figure 6C).  Essentially 
the same results were obtained when the L-glutamate secretion was evoked by ATP (Figure 
6D).  In contrast to the L-glutamate secretion, KCl-mediated secretion of bone degradation 
products was not altered in osteoclasts of all three mice genotypes (Figure 6E).   
 
mGluR8-mediated autoregulation of transcytosis 
Subsequently, we investigated the role of the released L-glutamate.  Since L-glutamate 
signaling in peripheral tissues usually involves an autoregulatory mechanism by way of 
metabotropic receptors (Yamada et al, 1998; Uehara et al, 2004), we investigated whether 
mGluRs are expressed in osteoclasts, and if so, whether they regulate transcytosis.  Among 
known mGluRs, RT-PCR indicated the presence of mRNAs of mGluR3, mGluR4 and 
mGluR8 in RAW 264.7 cells treated with RANKL and the presence of mGluR3, mGluR5 and 
mGluR8 in osteoclasts (Figure 7A and supplementary information, Figure S3).  
Immunoreactivity for mGluR8 (Figure 7B), but not mGluR3 and mGluR4 was detected by 
immunohistochemical analysis in RAW264.7 cells treated with RANKL (data not shown), 
suggesting expression of mGluR8 in mature osteoclasts.  
       It is important to ask whether mGluR8 regulates transcytosis.  Upon the addition of 
(1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I), a specific agonist of 
class III mGluRs (Acher et al, 1997), KCl-evoked secretions of both L-glutamate and bone 
degradation products decreased by about 90% and 87% of the control, respectively, and the 
inhibitions were blocked by the (R,S)-cyclopropyl-4-phosphonophenylglycine (CPPG), a 
specific antagonist (Toms et al, 1996) and dibutylylcAMP (DBcAMP), a non-hydrolyzable 
cAMP analogue (Figure 7C, D).  Agonists for other mGluRs and NMDA receptor did not 
affect the secretions of L-glutamate (data not shown).  mGluR8 is functionally coupled with 
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the Gi protein, and thus its stimulation decreases intracellular cAMP content (Nakanishi, 
1992).  Consistent with these observations, both ACPT-I and L-glutamate decreased cAMP 
content, which were fully recovered by CPPG (Figure 7E).  These results are consistent with 
the idea that mGluR8 was functionally expressed in mature osteoclasts and inhibited 
transcytosis through an inhibitory cAMP cascade.   
 
Blocking the glutamate signal stimulates the resorptive activity of osteoclasts 
To reveal the physiological relevance of L-glutamate-mediated autoregulation of 
transcytosis, we investigated whether blocking the L-glutamate signaling with CPPG 
affects bone resorption.  We monitored the area of bone resorption produced by 
osteoclasts on dentine slices as a functional marker for osteoclasts.  α-MEM contains 0.5 
mM L-glutamate, the concentration at which L-glutamate mediated autosuppression of 
transcytosis may occur.  Thus, under the culture conditions, CPPG stimulated the bone 
resorptive activity by 1.5 fold (Figure 8).  Eel calcitonin at 10 nM inhibited bone 
resorption (Figure 8).  These results suggest that blocking the glutamate signal stimulated 
bone resorptive activity by osteoclasts.   
       Finally, to determine whether preventing L-glutamate signaling causes phenotypic 
changes in the bone tissues, we assessed the bone mass of female VGLUT1 -/- mice using 
microCT.  Comparing the bone masses in wild type and homozygotes, the bone mass, 
expressed as a ratio of BV/TV, of homozygotes had decreased and was significantly lower 
by the age of 4 months and exhibited osteoporosis-like symptoms (Figure 9).  Essentially 
the same results were obtained in all homozygotes tested (n = 3).  
 
 
Discussion 
The present results demonstrated that bone-resorbing osteoclasts were the site of L-glutamate 
signaling. Osteoclasts exhibited a glutamatergic phenotype upon maturation.  Functional 
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VGLUT1 was inducibly expressed in osteoclasts as demonstrated by molecular biological, 
biochemical and immunohistochemical techniques.  VGLUT1 was associated with small 
clear vesicles and larger membrane vesicles that also contained bone degradation products 
(Figures 2 and 3).  L-Glutamate and bone degradation products were secreted through 
transcytosis.  L-Glutamate was not stored in vesicles of osteoclasts prepared from 
VGLUT1-/- mice.   Consequently, osteoclasts prepared from VGLUT1-/- mice did not 
secrete L-glutamate.  These results provided convincing evidence for the glutamatergic 
nature of osteoclasts. 
       Up until now transcytosis of bone degradation products has been characterized 
primarily by morphological methods (Nesbitt and Horton, 1997; Salo et al, 1997; Mulari et al, 
2003).  Little is known about the mechanism of transcytosis.  Since some of VGLUT1 
molecules were associated with transcytotic vesicles, we thus hypothesized that L-glutamate 
is co-localized and co-secreted with bone degradation products through transcytosis.  
Experiments were performed to characterize the secretion of L-glutamate and bone 
degradation products.  The secretion of both was found to require, at least partially, the 
influx of extracellular Ca2+.  Moreover, inhibition of both secretory activities by a class III 
mGluR agonist, and the reversion of this effect with a specific antagonist suggested the 
requirement of cAMP for both secretion processes (Figure 7).  Thus, secretion of 
L-glutamate and bone degradation products apparently involves regulated exocytotic 
processes that are similar to that in neurons and endocrine cells.  In addition, both secretory 
activities showed similar temperature dependence and sensitivities to bafilomycin A1 and 
nocodazole.  These results constitute evidence that L-glutamate and bone degradation 
products are secreted together through transcytosis.  To our knowledge, this is the first direct 
evidence that transcytosis contains a regulated process.  Presence of a regulated process in 
transcytosis suggests involvement of molecular machinery similar to that of the exocytotic 
pathway of neuronal synaptic vesicles and endocrine secretory granules.  Identification of 
molecular components involved in the transcytosis such as soluble 
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N-ethylmaleimide-sensitive attachment protein receptor (SNARE)-like proteins and 
voltage-gated Ca2+ channels in bone resorbing osteoclasts is urgently needed for full 
characterization of the regulated transcytosis.   
       Another important feature of transcytosis is the involvement of an ionotropic 
purinergic P2 receptor(s) in the process.  Osteoclasts as well as osteoblasts express multiple 
P2 receptor subtypes and an increasing amount of evidence has highlighted the importance of 
P2 receptors in the bone microenvironment and the bone remodeling processes (Gallagher 
and Buckley, 2002; Gartland et al, 2003).  Which P2 subtype triggers secretion of 
L-glutamate and bone degradation products is unknown and awaits further study.  Since 
ATP is released from osteoblasts upon mechanical stimulation (Romanello et al, 2001; 
Jørgensen et al, 2002), our results suggest that osteoblasts affect transcytosis of osteoclasts 
through ATP- and L-glutamate signaling pathways.   
       We propose the following secretory events during bone resorption: osteoclasts 
absorb bone degradation products through endocytosis and sequester them in transcytotic 
vesicles.  Afterwards, VGLUT1-containing vesicles (small clear vesicles shown in Figure 
3A) fuse with transcytotic vesicles and the resultant vesicles store both L-glutamate and bone 
degradation products (larger vesicles seen in Figure 3B).  Subsequently, L-glutamate and 
other internal materials are secreted together through exocytosis (Figure 10, left panel).   In 
osteoclasts of VGLUT1-/- mice, transcytotic vesicles apparently fused with vesicles 
containing no L-glutamate, which led to the secretion of bone degradation product without 
concomitant release of L-glutamate (Figure 10, right panel).  Thus, the secretory pathways 
for L-glutamate and bone degradation products overlapped, but were not dependent upon one 
another.  One can ask whether L-glutamate secretion is, at least in part, mediated through 
another secretory mechanism other than transcytosis, since the proportion of VGLUT1 
associated with transcytotic vesicles is not known.  This possibility seems to be unlikely, 
however, because the secretion of L-glutamate and bone degradation products shared similar 
biochemical and pharmacological characteristics as described above.  More detailed and 
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quantitative study will clarify this issue.  In any event, transcytosis of L-glutamate and bone 
degradation products appears to be a more complex secretory event than previously thought.     
       We have provided evidence that L-glutamate and bone degradation products were 
secreted through transcytosis.  Through this, L-glutamate may act in a paracrine/autocrine 
manner, allowing regulation of cellular function and/or differentiation by way of glutamate 
receptors (Mason, 2004).  In our studies, we found that mGluR8 decreased cAMP content 
and inhibited KCl-evoked secretion of L-glutamate and bone degradation products.  Thus, 
L-glutamate secreted through transcytosis may be involved in the negative feedback cascade 
for transcytosis (Figure 10).  This is reminiscent of L-glutamate signaling in pineal glands 
(Yamada et al, 1998) and islet of Langerhans (Uehara et al, 2004) that leads to the inhibition 
of melatonin synthesis and glucagon secretion by way of mGluR2/3 and mGluR4, 
respectively.  mGluR-coupled autoregulation may be a common feature of L-glutamate 
signaling in the peripheral tissue.   
       One of the significant findings in the present study is that VGLUT1-/- mice develop 
osteoporosis four months after birth (Figure 9).  Since glutamate signaling may involve a 
negative feedback regulation of transcytosis as described above, under normal physiological 
conditions, bone resorption should be suppressed by L-glutamate signaling.  The fact that 
blocking the L-glutamate-mediated autoregulatory cascade by an mGluR8 antagonist 
enhanced bone resorption supports this idea (Figure 8).  In osteoclasts of VGLUT1-/- mice 
the loss of the ability to secrete L-glutamate did not affect secretion of bone degradation 
products (Figure 6E).  Thus, the negative feedback regulation in osteoclasts is impaired in 
VGLUT1-/- mice, leaving the osteoclasts in a desuppressed state that led to elevated bone 
resorption that, in turn, led to osteoporosis (Figure 10, right panel).  Since purinergic 
stimulation facilitates L-glutamate secretion (Figure 5), it is expected that inhibition of 
purinergic signaling causes similar effects on osteoclastic activity.  In this respect, it is 
noteworthy that deletion of the ionotropic P2X7 receptor causes increased trabecular bone 
resorption (Ke et al, 2003).  To our knowledge, this is the first report presenting direct 
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evidence that impairment of glutamate signaling is associated with a metabolic disorder.  
Further studies, especially quantitative analyses as to interrelationship among glutamate 
signaling, transcytosis of bone degradation products and bone digestion, are necessary to 
elucidate the detailed signaling cascade and how impairment of glutamate signaling leads to 
osteoporosis.   
       The finding that transcytotic vesicles serve as storage organelles for L-glutamate 
expands the concept of the glutamate signaling.  In addition to neuronal synaptic vesicles, 
we have shown that VGLUTs are functionally associated with synaptic-like microvesicles in 
pinealocytes, hormone-containing secretory granules in islet α and F cells and intestinal L 
cells, and acrosomes of early spermatid (Moriyama and Yamamoto, 2004; Uehara et al, 2006).  
Transcytotic vesicles are the fifth organelles to show vesicular storage of L-glutamate.  
Transcytotic vesicles are morphologically and biochemically distinct from known secretory 
vesicles.  Further characterization of transcytotic vesicles as L-glutamate storage organelles, 
such as the intravesicular concentration of L-glutamate, pH and the kinetics of L-glutamate 
secretion are important to reveal the common aspects and diversity in L-glutamate signaling. 
       In conclusion, we have clarified the issues of when, where and how L-glutamate is 
secreted in bone tissues.  Glutamatergic signal transmission may play essential regulatory 
role(s) in bone homeostasis, since impairment of L-glutamate signaling stimulates bone 
resorptive activity, leading to osteoporosis.   
 
 
Materials and methods 
 
Cell cultures 
Primary osteoblasts were prepared from newborn ddY mice by sequential enzymatic 
digestion as previously described (Suda et al, 1997).  Osteoclasts were induced to 
differentiate into mature osteoclasts by the co-culture method described by Suda et al 
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(1997) with slight modifications.  More than 90% of the adherent cells were 
TRAP-positive, which were used for experiments after prolonged incubation.  To 
differentiation of osteoclasts from RAW 264.7 cells, the cells were treated with 100 ng/ml 
extracellular domain of RANKL (sRANKL) (Peprotech EC) and 10,000 units/ml 
macrophage colony-stimulating factor (Kyowa Hakko) as described (Toyomura et al, 2003).  
Primary osteoblasts and clonal bone cell lines including MC3T3-E1, MC3T3-G2/PA6, ST2 
(Udagawa et al, 1989) and C3H10T1/2 (Levine and Teegarden, 2004) were cultured as 
described. 
 
VGLUT1 knockout (-/-) mice 
A line of VGLUT1-/- mice was maintained as heterozygotes by continuous backcrossing 
with wild type +/+ C57/BL6 mice as described (Fremeau et al, 2004b).  Mice were 
genotyped by PCR (Fremeau et al, 2004b) before use. 
 
Reverse transcription polymerase chain reaction (RT-PCR) and Northern analysis 
Total RNA (1 µg) extracted from cultured cells was transcribed into cDNA in a final 
volume of 20 µl of a reaction buffer containing 0.2 mM each dNTP, 10 mM dithiothreitol, 
100 pmol of random octamers, and 200 units of Moloney murine leukemia virus reverse 
transcriptase (Amersham).  After 1 h incubation at 42 °C, the reaction was terminated by 
heating at 90 °C for 5 min.  The PCR amplification was performed as described (Hayashi 
et al, 2003a). The sequences of the oligonucleotides used as primers were based on the 
published sequences, and are shown in the supplementary Table IS.  DNA sequencing was 
performed by the chain termination method. For Northern blotting, the mRNA (4.5 µg per 
lane) was separated on a 1% agarose gel containing formaldehyde and then transferred to a 
nylon membrane (Amersham).  The immobilized RNA was probed with cDNA fragments 
of VGLUT (nt 270 – 706) labeled with [32P]-dCTP (3000 Ci/mmol, Amersham) by random 
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priming.  After extensive washing, the membrane was subjected to autoradiography using 
BAS 1000 film (Fuji Film Co.). 
 
Antibodies 
Site-specific polyclonal antibodies against rat VGLUT1, V-ATPase subunit A and mGluR4 
were prepared; their immunological specificities have been described elsewhere (Hayashi 
et al, 2003b; Uehara et al, 2004).  Guinea pig polyclonal antibodies against mGluR8 and 
rabbit polyclonal antibodies against mGluR2/3 were purchased from Chemicon.  The 
following antibodies were used as organelle markers: mouse monoclonal antibody 6C4 
(kindly supplied by Dr. T. Kobayashi, Riken, Wako, Japan); mouse monoclonal antibodies 
against α-tubulin (Sigma), transferrin receptor (NeoMarkers), cathepsin K (Oncogene 
Research Products), TGN38 (Transduction Laboratories), and GM130 (BD Transduction 
Laboratories); rat monoclonal antibodies against lamp2 (Developmental Studies 
Hybridoma Bank).  Alexa Fluor 488-labeled anti-rabbit IgG, Alexa Fluor 568-labeled 
anti-mouse IgG, and Alexa Fluor 568-labeled phalloidin were obtained from Molecular 
Probes and IgG conjugated with colloidal gold from British Biocell International Ltd. 
 
Western blotting 
Membrane fraction from RAW264.7 cells treated with RANKL or untreated cells (1 × 108 
cells each) were prepared and denatured with SDS sample buffer containing 1% SDS and 
10% β-mercaptoethanol.  Then, Western analysis was performed as described in Hayashi 
et al. (2003a).   
 
Immunohistochemistry 
The procedure of Hayashi et al. (2003a,b) was used.  In brief, cells on collagen-coated 
coverslips were fixed with 4% paraformaldehyde in PBS for 30 min, followed by a 15 min 
incubation in the PBS containing 0.1% Triton X-100, 2% goat serum and 1% bovine serum 
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albumin (BSA), and finally reacted with antibodies at 1 µg/ml or diluted 1000-fold 
(anti-VGLUT1 or other antibody) in PBS containing 0.5% BSA for 1 h at room 
temperature.  Samples were washed four times with PBS and then reacted with the 
secondary antibody for 1 h at room temperature.  The secondary antibodies used were 
Alexa Fluor 568-labeled anti-mouse IgG (1 µg/ml) or Alexa Fluor488-labeled anti-rabbit 
IgG (2 µg/ml) (Molecular Probes).  Finally, the immunoreactivity was examined under an 
Olympus FV300 confocal laser microscope. 
       For immunostaining of femur sections, mice were anesthetized with ether and then 
perfused intracardially with saline, followed by 4% paraformaldehyde in 0.1 M phosphate 
buffer (pH 7.4).  The femora were isolated and immersed in the same solution overnight at 
4 °C.  After washing with PBS, the femora were decalcified with 9% EDTA- 2Na and 
10% EDTA- 4Na in PBS at 4 oC for 1 week.  They were successively infiltrated with 30% 
sucrose in PBS, embedded in OTC compound (Sakura Finetek), sectioned at a thickness of 
6 µm, and then mounted on gelatin-coated slides.  The immunological reaction was 
performed as described above.  Histochemical staining for TRAP with horseradish 
peroxidase-diaminobenzidine (HRP-DAB) was performed as described (Nakamura et al, 
1994). 
 
Immunoelectron microscopy 
Samples were fixed with 0.2% glutaraldehyde and 4 % paraformaldehyde in 0.1 M 
phosphate buffer (pH 7.4), dehydrated, and then embedded in LR white for 2 days at 
-20 °C.  Ultrathin sections on nickel grids were incubated with PBS containing 2% goat 
serum and 2% BSA for 10 min, followed by an incubation with mixture of rabbit 
anti-VGLUT1 antiserum (diluted 50-fold) and mouse anti-FITC monoclonal antibodies 
(diluted 125-fold) for 1 h at room temperature, and, finally, an incubation with a mixture 
of secondary antibodies conjugated with colloidal gold for 15 min at room temperature 
(Hayashi et al, 2003a).  After washing with 0.1M sodium cacodylate buffer (pH 7.4), 
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the sections were postfixed in 5% glutaraldehyde in the cacodylate buffer, stained 
sequentially with uranyl acetate for 10 min and lead citrate for 1 min, and observed 
under a Hitachi H-7100S electron microscope. 
 
L-Glutamate uptake 
A membrane fraction of cultured cells was prepared as described above and used for the 
transport assay within a day of preparation; the samples were not frozen.  L-Glutamate 
uptake by membrane vesicles were measured as described in the solution comprising 
membranes (0.1 mg protein), 20 mM MOPS-Tris (pH 7.0), 5 mM Mg-acetate, 4 mM 
KCl, 0.3 M sucrose and 100 µM [3H]-L-glutamate in the presence or absence of ATP 
(Tris salt) at 30 °C (Moriyama and Yamamoto, 1995).  
 
Secretion of L-glutamate and fluorescent bone degradation products 
RAW-derived osteoclast-like cells or osteoclasts (2.0 × 105 cells/dish) were washed 
three times with Ringer’s solution and then incubated for 30 min at 37 °C.  The cells 
were incubated in Ringer’s solution and stimulated by the addition of either 50 mM KCl 
or 1 mM ATP (final concentrations).  When necessary, agonists or antagonists of 
glutamate receptors, obtained from Tocris Cookson (Avonmouth, UK), at the indicated 
concentrations were included.  At the times indicated, samples (100 µl) were carefully 
taken and the amount of L-glutamate was determined by HPLC with a RESOLVE C18 
column (4.6 mm × 150 mm; Waters Ltd.) and fluorescence detection as described 
previously (Hayashi et al, 2003a).  To measure secretion of bone degradation products, 
osteoclasts (1.0 × 103 cells) were cultured on dentine disks, which were labeled with the 
seminaphtofluorescein dye 5,6-carboxyl-SNAFL®-2 (Molecular Probes) as described by 
Stenbeck and Horton (2004).  After incubation for 12 h, the osteoclasts were stimulated 
by the addition of either 50 mM KCl or 1 mM ATP (final concentrations).  Then, 100 
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µl medium was carefully sampled and diluted with 1.9 ml glycine-NaOH (pH 10.0) and 
the fluorescence intensity measured. 
 
Measurement of cAMP 
cAMP was quantified with the enzyme immunoassay kit obtained from Cayman 
Chemical (Ann Arbor , Michigan), according to the manufacture’s manual.   
 
Measurement of bone resorption activity 
The resorption pit assay was performed as described by Li et al (2002).  Co-cultured 
osteoclasts on collagen gel-coated dishes were detached with 0.2% collagenase and 
plated on dentine slices and cultured in α-MEM medium containing 10% FBS in the 
presence or absence of 100 µM CPPG for 24 h.  In control experiments, eel calcitonin 
(Elcatonin, Asahi Chemical Industry Co. Tokyo) at 10 nM was included.  Resorption 
pits on the dentine slices were visualized by staining with Mayer’s hematoxylin, and 
observed under an Olympus BX60 microscope.  To quantify the resorption areas, five 
areas of dentine slices were randomly selected and stained resorption lacunae were 
measured with NIH Image program. 
 
Bone morphometry 
To assess the parameters for bone morphometry, 8 weeks and 4 months-old VGLUT1 
+/+ and VGLUT1-/- mice were anesthetized with ether and perfused intracardially with 
saline, followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4).  The 
femora were then isolated and immersed in the 4 % paraformaldehyde in PBS at 4 °C.  
The images were taken by micro focus X-ray computed tomography (ScanXmate-A080, 
COMSCAN TECNO CO. Ltd.), and reconstituted into 3D images with Fan CT.  Ratio 
of trabecular bone volume to total tissue volume (BV/TV) was calculated with analytic 
software (TRI/3D BON, Ratoc System Engineering Co. Ltd.) (Sone et al, 2004).  The 
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trabecular bone in the distal metaphysis of the femur was chosen as the sampling site, 
where was located from 0.5 mm to 1.5 mm from the growth plate. 
 
Data analysis 
All numerical values are shown as means + SEM (standard error of the mean).  n is the 
number of experiments.  The significance of differences between the mean values of 
two indicated groups was evaluated with the student’s t-test.  Statistical evaluations 
were performed using MS Excel (version 11.0). 
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